Infusion of neostigmine-glycopyrrolate for bowel evacuation in persons with spinal cord injury.
Defecatory complications are common after spinal cord injury (SCI) and have been attributed, in part, to an imbalance of the autonomic nervous system between parasympathetic and sympathetic effects on the colon. Because parasympathetic (i.e., cholinergic) input to the bowel may be downregulated after SCI, it was hypothesized that neostigmine, a medication that increases cholinergic tone by blocking the metabolism of acetylcholine, might promote bowel evacuation in these persons. Since neostigmine is known to cause bradycardia and bronchoconstriction, we also assessed whether these side-effects could be prevented by coadministration of neostigmine with glycopyrrolate, an anticholinergic agent that has limited activity on the muscarinic receptors of the colon. The hypothesis was tested in 13 persons with SCI in whom videofluoroscopy was carried out after instillation of a barium oatmeal paste into the rectum and descending colon. On separate days, subjects received, in a randomized, blinded design, one of three intravenous infusates (normal saline, 2 mg neostigmine, or 2 mg neostigmine + 0.4 mg glycopyrrolate). The effect of these infusates on bowel evacuation of the barium paste, heart rate, and airway resistance was determined. Both neostigmine and neostigmine + glycopyrrolate resulted in prompt bowel evacuation. The nadir heart rate was lower after neostigmine alone than with the combination. Neostigmine administration increased both total and central airway resistance, an effect that was not observed with the coadministration of glycopyrrolate. Other side-effects of neostigmine and the combination of drugs included muscle fasciculations and dry mouth, both of which were mild and short-lived. Abdominal cramping was noted in subjects with spinal cord lesions below thoracic level 10. These results indicated that neostigmine/glycopyrrolate administration is safe and well tolerated in persons with chronic SCI.
VA Medical Center, Bronx, New York, New York 10468, USA.
Mark A
MA
Korsten
Alan S
AS
Rosman
Anthony
A
Ng
Erdal
E
Cavusoglu
Ann M
AM
Spungen
Miroslav
M
Radulovic
Jill
J
Wecht
William A
WA
Bauman
D000328:Adult; D000403:Airway Resistance / Q000187:drug effects; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003672:Defecation / Q000187:drug effects*; D006024:Glycopyrrolate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009388:Neostigmine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010277:Parasympathomimetics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016037:Single-Blind Method; D013119:Spinal Cord Injuries / Q000188:drug therapy* / Q000503:physiopathology*; D016896:Treatment Outcome
D018680:Cholinergic Antagonists; D010277:Parasympathomimetics; D009388:Neostigmine; D006024:Glycopyrrolate